E-mail us

Bioavailability Enhancement for Insoluble Compounds & PROTAC & Oral Peptides

Recent statistics indicate that approximately 40% of currently marketed drugs and nearly 90% of candidates in R&D pipeline belong to Biopharmaceutics Classification System (BCS) II or IV poorly water-soluble drugs. Consequently, enhancing drug solubility and improving bioavailability are pressing challenges in the realm of new drug development. Widely employed methods for solubility enhancement include:

At Crystal Pharmatech, we specialize in overcoming the challenges associated with poorly water-soluble drugs. Our proven track record in crystallization and ASD formulation development, coupled with our commitment to scientific excellence, positions us as a reliable ally in achieving your scientific and regulatory goals.

API Salt Form Screening

Salt formation represents a straightforward and cost-effective method for solubilization. Organic weak acid or organic weak basic drugs can be converted into soluble salts, thereby increasing their solubility and improving oral bioavailability. Literature indicates that around 50% of drugs in the U.S. market exist in salt forms.

API Micronization

Micronization is a fluid dynamics-driven process that diminishes particle sizes to the micrometer range. In the context of APIs, micronization increases the specific surface area, porosity, and surface energy of the drug particles. This, in turn, enhances the solubility and bioavailability of poorly soluble drugs. Micronization has evolved into a well-established API technology, finding successful applications in both clinical and commercial products. 

Amorphous Solid Dispersion (ASD, Spray Drying & Hot-melt Extrusion)

For poorly water-soluble drugs, amorphous solid dispersion (ASD) stands out as the preferred formulation for oral dosage forms. Both spray drying and hot melt extrusion methods can be utilized to prepare ASD, enhancing solubility and oral bioavailability.


Spray Drying

The spray drying process is a particle engineering technique that is a proven approach to improving the solubility of poorly soluble compounds. It has been widely used to enhance bioavailability in drug manufacturing for the following advantages:


The core technical team at Crystal Pharmatech has solid knowledge and expertise in the fundamentals and scaling-up principles for spray drying process and commercialized several amorphous solid dispersion solid dosage form drug products. With our deep understanding of all quality and regulatory requirements and world-class manufacturing and analytical equipment, we are confident that we can support amorphous solid dispersion formulation development at high speed and with high quality.

Hot Melt Extrusion

HME is widely recognized as an effective technology that enhances the bioavailability of poorly soluble APIs, ultimately improving patient compliance and making the manufacturing process more efficient.



Nanocrystal drugs are characterized by particle sizes in the nanometer range, typically below 1 μm (practically ranging from 200 to 500 nm). Formulations utilizing nanocrystals exhibit very small particle sizes, offering distinctive properties and benefits. These include heightened drug solubility, expanded surface area, improved bioavailability, and accelerated drug release.

Related Platforms of Crystal Pharmatech

Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303